VTYX vs. DAWN, MIRM, ABCL, ELVN, COLL, PRTA, ARQT, SAVA, GYRE, and INVA
Should you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include Day One Biopharmaceuticals (DAWN), Mirum Pharmaceuticals (MIRM), AbCellera Biologics (ABCL), Enliven Therapeutics (ELVN), Collegium Pharmaceutical (COLL), Prothena (PRTA), Arcutis Biotherapeutics (ARQT), Cassava Sciences (SAVA), Gyre Therapeutics (GYRE), and Innoviva (INVA). These companies are all part of the "pharmaceutical preparations" industry.
Day One Biopharmaceuticals (NASDAQ:DAWN) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.
Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks.
Day One Biopharmaceuticals has a beta of -1.44, indicating that its share price is 244% less volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.
88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are owned by institutional investors. 8.4% of Day One Biopharmaceuticals shares are owned by company insiders. Comparatively, 18.2% of Ventyx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Day One Biopharmaceuticals had 1 more articles in the media than Ventyx Biosciences. MarketBeat recorded 3 mentions for Day One Biopharmaceuticals and 2 mentions for Ventyx Biosciences. Day One Biopharmaceuticals' average media sentiment score of 1.61 beat Ventyx Biosciences' score of 1.16 indicating that Ventyx Biosciences is being referred to more favorably in the news media.
Day One Biopharmaceuticals presently has a consensus price target of $37.67, suggesting a potential upside of 183.85%. Ventyx Biosciences has a consensus price target of $21.75, suggesting a potential upside of 355.02%. Given Day One Biopharmaceuticals' higher possible upside, analysts plainly believe Ventyx Biosciences is more favorable than Day One Biopharmaceuticals.
Ventyx Biosciences' return on equity of -57.28% beat Day One Biopharmaceuticals' return on equity.
Day One Biopharmaceuticals received 5 more outperform votes than Ventyx Biosciences when rated by MarketBeat users. Likewise, 58.18% of users gave Day One Biopharmaceuticals an outperform vote while only 49.09% of users gave Ventyx Biosciences an outperform vote.
Summary
Day One Biopharmaceuticals beats Ventyx Biosciences on 9 of the 15 factors compared between the two stocks.
Get Ventyx Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ventyx Biosciences Competitors List
Related Companies and Tools
